Slide 1: Wiltrom Co., Ltd
Stock Number: 6767 Wiltrom Co., Ltd 0
Slide 2: Safe Harbor Notice
Safe Harbor Notice Except for historical information set forth herein, this presentation contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied by such statements. Investors sh
Slide 3: Outline
Outline Company Profile Product introduction and Development Progress Market Estimation and Business Development Financial Results Future Outlook and Conclusion 2
Slide 4: Company Profile (TPEx, 6767)
Company Profile (TPEx, 6767) Company Portfolio ● Establish: Dec. 2009 (A spin-off company from ITRI) ● Paid in Capital: NTD$ 291,090,000 ● Employee: ~45 ● A company devoted to MIS spinal surgery with a completed product line Wiltrom Co., Ltd RD & RA (Taiwan) ● The company has 48 patents across four
Slide 5: History Achievements
History Achievements 2009 Wiltrom Co., Ltd has set up an ITRI Technology Extension. First Taiwanese company obtains TFDA approval with own-brand - 2014 minimally invasive spinal fixation system. 2016 Established an R&D center focusing on an independent and Innovative integration platform First Taiwa
Slide 6: Management Team
Management Team Huang-Chien Liang, PhD Jack Su Terry Tsai Director, Legal & Regulatory Affairs Chief Executive Officer and President Director and Chief Operating Officer (COO) 13+ years of experience in IP, legal & regulatory Affairs 20+ years of experience in biomaterial and 20+ years of experience
Slide 7: Outline
Outline Company Profile Product introduction and Development Progress Market Estimation and Business Development Financial Results Future Outlook and Conclusion 6
Slide 8: Product Line
Product Line Product Line Spinal Fusion Vertebral Compression Fracture Bone Cement Global TAM US$8.2B US$1.15B US$1.32B Spinal Fixation System Vertebral Bone Cement Augmentation System Low to Midden 龍蝦釘 Tripod-Fix - Viscosity Pedicle size Interbody Fusion System (5.5-7.0mm) Bone Graft Subs
Slide 9: IP protection in Wiltrom
IP protection in Wiltrom • Robust patent system in Wiltrom: continue to discover and apply patents for innovative R&D outcomes. • Focus on high value and innovative product. Tripod-Fix is the latest product, but has been awarded with 20 patents in major markets including US, EU, CN, AU and etc. numb
Slide 10: Product Pipeline and Progress
Product Pipeline and Progress Items 2023 2024 2025 2026 2027 2028 Tripod-Fix MDD to MDR Transition TW PMS I TW PMS II TW PMS III EU PMCF IDE Approval FDA Clinical Trail FDA approval Optimization of existing products Preventive product development * PMCF: post-market clinical follow-up (歐洲法規要求上市後臨床追蹤
Slide 11: Product Innovation for Market Growth
Product Innovation for Market Growth Spinal Fixation System Vertebral Augmentation System - Tripod-Fix • The only expandable system for anterior vertebral collapse ideal for height restoration in wedge fractures. • During placement, the anatomic support of the 3-leg pyramid design increases stabilit
Slide 12: Outline
Outline Company Profile Product introduction and Development Progress Market Estimation and Business Development Financial Results Future Outlook and Conclusion 11
Slide 13: Evolution of Surgical Approach in VCF Treatment
Evolution of Surgical Approach in VCF Treatment VCF: Vertebral Compression Fracture 1st Vertebroplasty 2nd Balloon Kyphoplasty 3rd Expandable Device Directly inject cement into Use an inflated balloon to restore the Use the mechanical expandable device to a fractured vertebral body fractured vertebr
Slide 14: Highly Prevalent and Growing Disease
Highly Prevalent and Growing Disease Osteoporotic Vertebral Compression Fracture 13
Slide 15: Accelerating European Market Expansion
Accelerating European Market Expansion Global Market Share(%) by Geography VCF Value By Geography in Europe 10% 1% 1%1% % 0% 0% 1%2%1% Germany 2% No.1 2% France 3% Italy 28% Asia-Pacific 33% 4% United Kingdom Europe 4% 47% Turkey Middle East and Africa 4% Ireland South and Central America Spain Nort
Slide 16: Business Development Strategy
Business Development Strategy Strategic Partner: Germany, Italy, France Distributor: Spain, Greece, Poland, Slovenia, Austria, Switzerland, Portugal, Belgium…etc 15
Slide 17: Outline
Outline Company Profile Product introduction and Development Progress Market Estimation and Business Development Financial Results Future Outlook and Conclusion 16
Slide 18: Q1-Q3/2023 Financial Results
Q1-Q3/2023 Financial Results (In Thousands of New Taiwan Dollars) GROW 37.6% ACCOUNT 2022年 Q1~Q3 2023年 Q1~Q3 DIFF YOY OPERATING REVENUE 152,979 210,540 57,561 37.6% NET OPERATING INCOME(LOSS) (5,948) (9,658) (3,710) 62.4% NON-OPERATING INCOME AND EXPENSES (5,796) 18,370 24,166 -416.9% (INCOME)LOSS F
Slide 19: Operating Revenue
Operating Revenue (In Thousands of New Taiwan Dollars) Q1-Q3/2023 18
Slide 20: Revenue Breakdown(2022 vs. 2023)
Revenue Breakdown(2022 vs. 2023) (In Thousands of New Taiwan Dollars) For Taiwan revenue, compared to last year, $56,037, 41% YoY. For Foreign revenue, compared to last year, $1,523, 10% YoY. 19
Slide 21: Global Revenue Statistics (2022 vs. 2023)
Global Revenue Statistics (2022 vs. 2023) (In Thousands of New Taiwan Dollars) Compared to last year, 2023 YoY Strong revenue growth was driven by new clients, including Europe, SEA, America, and others. 20
Slide 22: Outline
Outline Company Profile Product introduction and Development Progress Market Estimation and Business Development Financial Results Future Outlook and Conclusion 21
Slide 23: Future Outlook
SEA: Southeast Asia Future Outlook LATAM: Latin America ME: Middle East TF: Tripod-Fix CDMO: Contract Development and Manufacturing Organization Wiltrom’s 2nd Curve Moment CE MDR Transfer US Market Preparation FDA Clinical Trial Kick-off CDMO Capacity Scale-up Evidence Marketing 2023 2024 2025 2026
Slide 24: Conclusion
Conclusion • Revenue has continued to grow steadily in recent years. • We have expanded our sales to overseas markets. • Clinical validation will boost our market share. • We are continuing to introduce new products to consolidate our market position. 23